PBM Mail-Order Mandates Cause Cold-Chain Failures for Biologics

PBMs increasingly mandate that maintenance medications and specialty drugs be filled through their own mail-order pharmacies rather than local pharmacies. For temperature-sensitive medications — including insulins, biologics, and certain eye drops — this means shipping drugs through UPS, FedEx, or USPS in thermal packaging that must maintain strict temperature ranges (typically 36-46 degrees F) for the duration of transit. When packages sit on a doorstep in July heat or freeze in a January mailbox, the medication is compromised. Patients often cannot tell by looking whether a biologic has been degraded. The scale of the problem is significant. A 2022 survey by the Specialty Pharmacy Times found that 14% of patients receiving mail-order specialty medications reported at least one delivery where the cold pack was warm or melted upon arrival. For insulin specifically, the American Diabetes Association notes that insulin exposed to temperatures above 86 degrees F begins to degrade, losing potency unpredictably. A patient injecting degraded insulin experiences unexplained blood sugar spikes, which they may attribute to diet or disease progression rather than a compromised medication. The patient harm cascades. Unexplained glucose spikes lead to dosage increases, which lead to hypoglycemia risk when the patient later receives properly stored insulin. For biologic medications used in autoimmune diseases, a degraded dose can trigger disease flares that take weeks to restabilize. Patients and physicians troubleshoot the clinical deterioration without considering that the drug itself was damaged in transit, leading to unnecessary treatment changes, additional testing, and increased healthcare utilization. Mail-order mandates persist because PBM-owned mail-order pharmacies are enormously profitable. The PBM captures both the dispensing margin and the administrative fee, eliminates the independent pharmacy from the transaction, and processes prescriptions at scale with lower per-unit labor costs. CVS Caremark, Express Scripts, and OptumRx each report mail-order and specialty pharmacy revenue in the tens of billions annually. The financial incentive to mandate mail-order is so strong that PBMs impose penalty copays — charging patients $20 more per fill — if they use a local pharmacy instead. The structural issue is that there is no federal standard for pharmaceutical cold-chain shipping to patients' homes. FDA's cold-chain regulations cover manufacturer-to-distributor and distributor-to-pharmacy shipments, but the last mile to the patient's mailbox is largely unregulated. PBMs self-certify their shipping processes, and there is no independent verification that temperature was maintained throughout transit. The patient has no way to test whether their medication was compromised, and the PBM has no liability for temperature excursions that occur after the package leaves their facility.